Neuroprotective strategies in COVID-19

Julio César García Rodríguez, Alina González Quevedo

Texto completo:

HTML PDF

Resumen

Considering the Release published by the Cuban Academy of Sciences in the face of the enormous local and global challenges associated with the COVID-19 pandemic, it is necessary that all the Cuban scientific community be placed in the management and investigation of this disease. Since the XVI century our country has been confronting epidemic outbreaks in political and social conditions very different from what we now have. SARS-CoV-2 (CoV-2) is the new coronavirus, which causes the disease coined by WHO as COVID-19 since February 2020. Different countries have reported CNS manifestations, but neuroprotective strategies have not been implemented. In the present article we provide a brief overview of the neurological manifestations which have been reported during the COVID-19 pandemic. We also highlight the importance not only of treating the immediate damage to the CNS caused by the virus in these patients, but also suggest the introduction of a neuroprotective agent, such as intranasal Neuro-EPO –a Cuban molecule capable of potentiating the endogenous defenses of the brain– which could prove to be effective in locally diminishing the immediate and possibly long term damage of the virus on the nervous system.

Palabras clave

COVID-19; SARS-CoV-2; pandemic; neuroprotection; neurological symptoms

Enlaces refback

  • No hay ningún enlace refback.




Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.